EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-site evaluation of moxifloxacin and gatifloxacin on the Sensititre dried susceptibility plate compared to NCCLS microdilution method



Multi-site evaluation of moxifloxacin and gatifloxacin on the Sensititre dried susceptibility plate compared to NCCLS microdilution method



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 172



Background: A multi-site evaluation was undertaken to compare the performance of MOX (Bayer, West Haven, CT) and GAT (BMSQ, Princeton, NJ) on the Sensititre 18-24 hour susceptibility dried plate to the NCCLS M7-broth microdilution reference method, testing both automated and manual reading methods. The range tested for both MOX and GAT was (0.004-16 ug/ml). Methods: The clinical evaluation was conducted at three sites and consisted of 306 fresh clinical gram-negative isolates and 75 CDC challenge isolates, which included both Enterobacteriaciae and non-enterobacteriaciae. Recommended quality control organisms were tested daily and were within the NCCLS expected quality control range. Results: For MOX, when the automated reading method was compared to the reference method the total isolates' Essential Agreement (EA) and Categorical Agreement (CA) were 96.3% and 96.9%, respectively. When the manual reading method was compared to the reference method the EA and CA were 97.6% and 97.9%, respectively. For GAT, when the automated reading method was compared to the reference method the total isolates' EA and CA were 97.4% and 98.4%, respectively. When the manual reading method was compared to the reference method the EA and CA were 97.6% and 99%, respectively. For MOX, the reproducibility EA and CA were 100% and 98% for the automated method and 97.3% and 93.3% for the manual method. For GAT, the reproducibility EA and CA were 98.7% and 96% for the automated method and 100% and 97.3% for the manual method. Conclusions: This multi-site evaluation indicates that the performance of MOX and GAT on the Sensititre 18-24 hour susceptibility system, using either the automated or manual reading method, was equivalent to its performance using the NCCLS M7-broth microdilution reference method.

(PDF 0-2 workdays service: $29.90)

Accession: 035349522

Download citation: RISBibTeXText



Related references

Multi-site evaluation of gatifloxacin on the sensititre dried susceptibility panel compared to NCCLS microdilution method. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 138, 2000

Multi-site evaluation of moxifloxacin on the sensititre dried susceptibility panel compared to NCCLS microdilution method. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 138, 2000

Multi-site evaluation of gatifloxacin, moxifloxacin, cefotaxime, cefdinir, and meropenem comparing Haemophilus influenzae on both the Sensititre dried susceptibility panel and the NCCLS microdilution method. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 131, 2002

Multi-site evaluation of Daptomycin on the Sensititre dried susceptibility plate compared to NCCLS microdilution method. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 172, 2003

Multi-site evaluation of Cefdinir and Meropenem on the Sensititre dried susceptibility panel compared to NCCLS microdilution method. Abstracts of the General Meeting of the American Society for Microbiology 99: 121, 1999

A multi-site evaluation of Sparfloxacin comparing the Sensititre dried susceptibility panel to the NCCLS microdilution method. Abstracts of the General Meeting of the American Society for Microbiology 101: 171, 2001

A multi-site evaluation of Levofloxacin comparing the Sensititre dried susceptibility panel to the NCCLS microdilution method. Abstracts of the General Meeting of the American Society for Microbiology 101: 171-172, 2001

Multi-site evaluation of cefdinir, linezolid, meropenem, and synercid on both the Sensititre dried susceptibility panel and the NCCLS microdilution method. Abstracts of the General Meeting of the American Society for Microbiology 100: 204, 2000

Multisite evaluation of five new quinolones on the sensititre dried susceptibility panel as compared to NCCLS microdilution method. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 140, 1998

An evaluation of Gemifloxacin, Trovafloxacin and Ciprofloxacin on the Sensititre Dried Susceptibility Panel as compared to NCCLS microdilution method. Abstracts of the General Meeting of the American Society for Microbiology 100: 204, 2000

Evaluation of the Sensititre Autoreader compared to NCCLS microdilution method for antimicrobial susceptibility testing of Streptococcus pneumoniae. Abstracts of the General Meeting of the American Society for Microbiology 101: 170, 2001

A multi-site comparison study of the Sensititre (R) Automated/Manual susceptibility plate to the CLSI microdilution method for Streptococcus spp.. Abstracts of the General Meeting of the American Society for 107): 133-134, 2007

Comparison of the Sensititre YeastOne colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species. ChemoTherapy 48(1): 21-25, 2002

An equivalency study of GAR 936, Minocycline, and Piperacilin on the SensititreTM dried Susceptibility Panels as compared to NCCLS microdilution method. Abstracts of the General Meeting of the American Society for Microbiology 101: 220, 2001

Comparison of the sensititre yeastone colorimetric method with the NCCLS broth microdilution modified reference method for amphotericin B, fluconazole, itraconazole and voriconazole susceptibility testing against Candida non-albicans species. Journal de Mycologie Medicale 13(4): 168-174, Decembre, 2003